Comparative Pharmacology
Head-to-head clinical analysis: LOPERAMIDE HYDROCHLORIDE versus MYTESI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPERAMIDE HYDROCHLORIDE versus MYTESI.
LOPERAMIDE HYDROCHLORIDE vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide binds to µ-opioid receptors in the intestinal wall, reducing propulsive peristalsis and increasing intestinal transit time. It also inhibits calcium-calmodulin-dependent pathways, decreasing electrolyte and water secretion, and enhances anal sphincter tone.
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
4 mg orally initially, followed by 2 mg after each unformed stool; maximum 16 mg per day. For chronic diarrhea, 4 mg orally once, then 2 mg after each unformed stool until diarrhea controlled; typical maintenance 4-8 mg daily in divided doses. Traveler's diarrhea: 4 mg initially, then 2 mg after each loose stool; maximum 8 mg per day for up to 2 days.
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Terminal elimination half-life is 9-14 hours (mean 10.8 hours) in adults; may be prolonged in hepatic impairment.
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Primarily fecal (30-40% as unchanged drug, 50-60% as metabolites); renal excretion accounts for <5% of unchanged drug and ~10% of metabolites.
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category A/B
Category C
Antidiarrheal
Antidiarrheal